Good news! Cancer is history (soon)! It appears there are no specific research papers available yet.
"... Combining use of the new vaccine with Merck’s immunotherapy drug Keytruda over a three-year period reduced the chances of relapse or death from skin cancer by 49 percent compared to using Keytruda alone. Additionally, patients saw a 62% reduction in the fatality rate and the rate of cancer spread when using both treatments. ...
It works by telling the participant’s cells to produce 34 neoantigens — proteins found only in the cancer cells. Meanwhile, Keytruda enhances the body’s immune response to tumour cells. The neoantigens trigger an immune response, thus further preparing the body to act against cells producing them. The vaccine is “personalized” for each patient, based on the mutational signature of the DNA sequence of the tumor. It’s aimed at preventing the tumor from coming back. ...
Merck and Moderna have now started a phase 3 trial with the combination of the new vaccine with the immunotherapy drug Keytruda. They will enroll around 1,000 people with stage IV melanoma. Final results are expected by 2028. However, the expectation is that the phase 3 will be used as a confirmatory study. ..."
Merck and Moderna have now started a phase 3 trial with the combination of the new vaccine with the immunotherapy drug Keytruda. They will enroll around 1,000 people with stage IV melanoma. Final results are expected by 2028. However, the expectation is that the phase 3 will be used as a confirmatory study. ..."
No comments:
Post a Comment